http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014036865-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02f24694b4445e31254823f04656311e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C215-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C213-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C215-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 |
| filingDate | 2013-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e311ecb511b5d7473d1e088d0a6a3dde http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_350f5068065c1c1b90abc37cb78ecf1f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da68e557f9c5b74e96d0948b4be5836d |
| publicationDate | 2014-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2014036865-A1 |
| titleOfInvention | Method for preparing fingolimod mucate and crystal thereof and application of fingolimod mucate and crystal thereof |
| abstract | The present invention relates to fingolimod mucate, a crystal form A thereof and a preparation method for the fingolimod mucate and the crystal form A thereof. The crystal form A has characteristic peaks in an X-ray powder diffraction pattern obtained by the diffraction of Cu Kα rays when 2θ is about 6.1, 9.1, 12.2, 14.9, 15.7, 17.8, 18.5, 19.6, 20.6, 21.4, 21.8, 22.5 and 24.5 degrees. The present invention also relates to the application of the crystal form A to the preparation of a medicament which is taken as a sphingosine-1-phosphate (S1P) receptor modulator, in particular to the application of the crystal form A to the preparation of a medicament which is taken as an immunomodulator. In addition, the present invention also provides a pharmaceutical composition, which comprises the fingolimod mucate or the crystal form A and a pharmaceutically acceptable carrier. |
| priorityDate | 2012-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 46.